Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence.
Paweł RogalaAnna Małgorzata CzarneckaBozena Cybulska-StopaKrzysztof OstaszewskiKarolina PiejkoMarcin ZiętekRobert DziuraEwa RutkowskaŁukasz GalusNatasza Kempa-KamińskaJacek CalikAgata Sałek-ZańTomasz ZemełkaWiesław BalAgnieszka KamyckaTomasz ŚwitajGrażyna Kamińska-WinciorekRafał SuwinskiJacek MackiewiczPiotr Lukasz RutkowskiPublished in: Journal of clinical medicine (2022)
BRAFi/MEKi therapy is effective in the second-line in advanced and metastatic melanoma patients. For the first time, the efficacy of all BRAFi/MEKi combinations as second-line therapy is shown.